Unmet needs in pneumonia research: a comprehensive approach by the CAPNETZ study group DOI Creative Commons
Mathias W. Pletz, Andreas Vestergaard Jensen, Christina Bahrs

и другие.

Respiratory Research, Год журнала: 2022, Номер 23(1)

Опубликована: Сен. 10, 2022

Abstract Introduction Despite improvements in medical science and public health, mortality of community-acquired pneumonia (CAP) has barely changed throughout the last 15 years. The current SARS-CoV-2 pandemic once again highlighted central importance acute respiratory infections to human health. “network excellence on Community Acquired Pneumonia” (CAPNETZ) hosts most comprehensive CAP database worldwide including more than 12,000 patients. CAPNETZ connects physicians, microbiologists, virologists, epidemiologists, computer scientists Europe. Our aim was summarize situation research identify pressing unmet needs research. Methods To areas future research, followed a multiple-step procedure. First, members were individually asked needs. Second, top 100 experts field for their insights about (Delphi approach). Third, internal external discussed at scientific retreat. Results Eleven topics identified: detection causative pathogens, next generation sequencing antimicrobial treatment guidance, imaging diagnostics, biomarkers, risk stratification, antiviral antibiotic treatment, adjunctive therapy, vaccines prevention, systemic local immune response, comorbidities, long-term cardio-vascular complications. Conclusion Pneumonia is complex disease where interplay between system comorbidities not only impose an immediate but also affect patients’ developing as well up decade after resolved. review shown that there are still major shortcomings our knowledge CAP.

Язык: Английский

Surveillance of Invasive Pneumococcal Disease in Spain Exploring the Impact of the COVID-19 Pandemic (2019-2023) DOI Creative Commons
Covadonga Pérez-García, Julio Sempere, Sara de Miguel

и другие.

Journal of Infection, Год журнала: 2024, Номер 89(2), С. 106204 - 106204

Опубликована: Июнь 19, 2024

Dynamic trends of invasive pneumococcal disease (IPD) including the evolution prevalent serotypes are very useful to evaluate impact current and future conjugate vaccines (PCVs) rise non-vaccine serotypes. In this study, we include epidemiological patterns S. pneumoniae before after COVID-19 pandemic.

Язык: Английский

Процитировано

21
Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study DOI Creative Commons
Naïm Ouldali, Emmanuelle Varon, Corinne Lévy

и другие.

The Lancet Infectious Diseases, Год журнала: 2020, Номер 21(1), С. 137 - 147

Опубликована: Июль 20, 2020

Язык: Английский

Процитировано

104
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies DOI Creative Commons

Heather L. Sings,

Philippe De Wals, Bradford D. Gessner

и другие.

Clinical Infectious Diseases, Год журнала: 2018, Номер 68(12), С. 2135 - 2143

Опубликована: Окт. 22, 2018

The 13-valent pneumococcal conjugate vaccine (PCV13) is the only licensed PCV with serotype 3 polysaccharide in its formulation. Postlicensure PCV13 effectiveness studies against invasive disease (IPD) children have shown inconsistent results. We performed a systematic review and meta-analysis of observational to assess (VE) for IPD children. systematically searched PubMed, Embase, Cochrane library published before 14 August 2017. identified 4 2 conference posters that provided VE estimates stratified by serotype. pooled from random-effects was 63.5% (95% confidence interval [CI], 37.3%-89.7%). A sensitivity analysis including gave estimate 72.4% CI, 56.7%-88.0%). data case-control similar methodologies high quality support direct protection

Язык: Английский

Процитировано

93
Nationwide Trends of Invasive Pneumococcal Disease in Spain From 2009 Through 2019 in Children and Adults During the Pneumococcal Conjugate Vaccine Era DOI
Sara de Miguel, Mirian Domenech, Fernando González‐Camacho

и другие.

Clinical Infectious Diseases, Год журнала: 2020, Номер 73(11), С. e3778 - e3787

Опубликована: Сен. 28, 2020

Introduction of pneumococcal conjugate vaccines (PCVs) has reduced the disease caused by vaccine serotypes in children, providing herd protection to adults. However, emergence nonvaccine is great concern worldwide.This study includes national laboratory data from invasive (IPD) cases that affected pediatric and adult populations during 2009-2019. The impact implementing different strategies for immunocompetent adults comparing Spanish regions used 13-valent PCV (PCV13) vs 23-valent polysaccharide (PPV23) was also analyzed 2017-2019.The overall reductions IPD PCV13 children were 88% 59%, respectively, 2009-2019, with a constant increase serotype 8 since 2015. additional covered PPV23 increased 20% 2009 52% 2019. In 24F most frequent 2019, whereas 3 accounted 36% or calendar certain up 25% 11%, showing decrease when used.Use epidemiology, reducing burden but protection; however, worrisome. Vaccination seems control including 3.

Язык: Английский

Процитировано

93
New insights into the mycobacterial PE and PPE proteins provide a framework for future research DOI Creative Commons
Louis S. Ates

Molecular Microbiology, Год журнала: 2019, Номер 113(1), С. 4 - 21

Опубликована: Окт. 29, 2019

The PE and PPE proteins of Mycobacterium tuberculosis have been studied with great interest since their discovery. Named after the conserved proline (P) glutamic acid (E) residues in N-terminal domains, these are postulated to perform wide-ranging roles virulence immune modulation. However, technical challenges studying encoding genes hampered elucidation molecular mechanisms leave many open questions regarding biological functions mediated by proteins. Here, I review shared unique characteristics from a perspective linking this information mycobacterial virulence. discuss how different subgroups (PE_PGRS, PPE-PPW, PPE-SVP PPE-MPTR) defined why classification paramount importance understand as individuals or groups. goal MicroReview is summarize structure existing on gene family into simplified framework thinking about genes. Thereby, hope provide helpful starting points for researchers backgrounds. This has particular implications design monitoring novel vaccine candidates understanding evolution M. complex.

Язык: Английский

Процитировано

87
Sugar-Coated Killer: Serotype 3 Pneumococcal Disease DOI Creative Commons

Jennifer N. Luck,

Hervé Tettelin, Carlos J. Orihuela

и другие.

Frontiers in Cellular and Infection Microbiology, Год журнала: 2020, Номер 10

Опубликована: Дек. 23, 2020

Capsular polysaccharide (CPS), which surrounds the bacteria, is one of most significant and multifaceted contributors to Streptococcus pneumoniae virulence. Capsule prevents entrapment in mucus during colonization, traps water protect against desiccation, can serve as an energy reserve, protects bacterium complement-mediated opsonization immune cell phagocytosis. To date, 100 biochemically serologically distinct capsule types have been identified for S. ; 20 30 well-defined propensity cause opportunistic human infection. Among these, serotype 3 perhaps problematic infections are characterized having severe clinical manifestations including empyema, bacteremia, cardiotoxicity, meningitis; consequently, with a fatality rate 30%–47%. Moreover, resists antibody-mediated clearance despite its inclusion current 13-valent conjugate vaccine formulation. This review covers role pneumococcal pathogenesis importance on disease. We discuss how synthesis presentation bacterial surface from other serotypes, biochemical physiological properties this type that facilitate ability disease, why existing vaccines unable confer protection. conclude discussion clonal these changed since introduction 2000.

Язык: Английский

Процитировано

86
Streptococcus pneumoniae epidemiology, pathogenesis and control DOI
Ana Rita Narciso, Rebecca S. Dookie,

Priyanka Nannapaneni

и другие.

Nature Reviews Microbiology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 6, 2024

Язык: Английский

Процитировано

10
Evolution of Streptococcus pneumoniae Serotype 3 in England and Wales: A Major Vaccine Evader DOI Open Access
Natalie Groves, Carmen Sheppard, D Litt

и другие.

Genes, Год журнала: 2019, Номер 10(11), С. 845 - 845

Опубликована: Окт. 25, 2019

Despite its inclusion in pneumococcal conjugate vaccine 13 (PCV13), Streptococcus pneumoniae serotype 3 remains a major cause of invasive disease England and Wales. Previous studies have indicated that there are distinct lineages within clonal complex 180 the clade distributions shifted recent years with emergence II. We undertook whole genome sequencing genomic analysis 616 isolates from Wales between 2003 2018, including carriage isolates. Our investigations showed II has expanded since 2014 now represents 50% (IPD) Genomic antibiotic resistance protein antigen genes profiles present clades which could account for this clade. This investigation highlights importance utility routine ability to identify new emerging variation at single nucleotide level informs surveillance will impact future development.

Язык: Английский

Процитировано

71
Dynamic changes in otopathogens colonizing the nasopharynx and causing acute otitis media in children after 13-valent (PCV13) pneumococcal conjugate vaccination during 2015–2019 DOI
Ravinder Kaur,

Naoko Fuji,

Michael E. Pichichero

и другие.

European Journal of Clinical Microbiology & Infectious Diseases, Год журнала: 2021, Номер 41(1), С. 37 - 44

Опубликована: Авг. 25, 2021

Язык: Английский

Процитировано

46
Changes in serotype prevalence of Streptococcus pneumoniae in Southampton, UK between 2006 and 2018 DOI Creative Commons
David Cleary, Jessica Jones, Rebecca A. Gladstone

и другие.

Scientific Reports, Год журнала: 2022, Номер 12(1)

Опубликована: Авг. 3, 2022

Streptococcus pneumoniae continues to cause significant disease burden. Whilst pneumococcal conjugate vaccines (PCV) have substantially reduced this burden, serotype replacement partially negates success due increased associated with non-vaccine serotypes (NVTs). Continued surveillance is therefore essential provide crucial epidemiological data. Annual cross-sectional of paediatric carriage was started in Southampton, UK following PCV7 roll-out 2006. Nasopharyngeal swabs were collected from children < 5 years old each winter (October March) 2006/07 and for consecutive year until 2017/18. Pneumococcal inferred whole genome sequencing A total 1429 (32.5%) pneumococci isolated 4093 children. Carriage ranged 27.8% (95%CI 23.7-32.7) 2008/09 37.9% 32.8-43.2) 2014/15. Analyses showed that aged 24-35 months (p 0.001) 47-60 0.05). PCV decreased markedly and/or PCV13 introduction, apart 3 where the relative frequency slightly lower post-PCV13 (pre-PCV13 n = 7, 1.67%; 13, 1.27%). Prevalence NVTs implicated low 24F (n 19, 1.4%) being most common followed by 9N 11, 0.8%), 8 0.5%) 12F 3, 0.2%).

Язык: Английский

Процитировано

31